secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001193125-24-161662
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo BioPharma prices $50M registered direct offering of 12.5M ADS at $3.99/ADS
--------------------------------------------------------------------------------

- Gross proceeds $50M from 12,531,300 ADS at $3.99 each; net proceeds ~$45.9M after expenses.
- Underwriters: Jefferies, Leerink Partners, and Cantor Fitzgerald acting as joint book-runners.
- New investors include Frazier Life Sciences, Deerfield Management, and Perceptive Advisors; existing holder participation.
- Net proceeds to fund setrusumab program (supply and pre-launch in Europe) and general corporate purposes.
- Offering expected to close on June 17, 2024, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312524161662/0001193125-24-161662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312524161662/d828399d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-161662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer